[Pharmacological study of a new adrenergic beta receptor blocking agent: 1-isopropylamino-3-(1,2,3,4-tetrahydro-1,4-ethano-5-naphthoxy)-2-propanol hydrochloride (K4423)].
D000433:1-Propanol / Q000008:administration & dosage / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D000605:Amino Alcohols / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000517:prevention & control; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002415:Cats; D003326:Coronary Circulation / Q000187:drug effects; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D007275:Injections, Intravenous; D051379:Mice; D009284:Naphthols / Q000008:administration & dosage / Q000494:pharmacology*; D011437:Propylamines / Q000008:administration & dosage / Q000494:pharmacology; D011817:Rabbits; D051381:Rats
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D009284:Naphthols; D011437:Propylamines; D000433:1-Propanol
Studio farmacologico di un nuovo bloccante i recettori simpatici beta-adrenergici: l'1-isopropilamino-3-(1,2,3,4-tetraidro-1,4-etano-5-naftossi)-2-propanolo cloridrato (K4423.